San Francisco and Berlin, February 12, 2025 (Globe Newswire) -T-Knife Therapeutics, Inc., a biharmaceutical company that develops T-cell receptor (TCR) designed T-cell therapies (TCR-T) to fight cancer, today announced that today that today announced that today announced that it today announced that TCR members of the company’s management team will participate in two investor conferences in March.

• TD COWEN 45^Th Annual Health Care Conference from March 3-5, 2025 in Boston, MA
• Leerink Partners Global Healthcare Conference from March 10-12, 2025 in Miami, FL

About T-Knife Therapeutics
T-knife is a biopharmaceutical company that is dedicated to developing T-cell receptor (TCR) designed T-cell therapies (TCR-TS) that delivers broad, deep and sustainable answers to solid tumor cancer patients. The company’s unique approach utilizes its own platforms and synthetic biological abilities to design the next generation of super-charged TCRS with best-in-class potential.

The company’s lead program, TK-6302, is an overcharged PAME that is focused on TCR-T that includes new improvements to improve T-cell condition and persistence, to overcome the immunosuppressive tumor micro-environment and to improve the durability of the response. The company plans to submit a clinical trial application (CTA) in the autumn of 2025 to initiate a clinical phase 1/2 of TK-6302 2026.

T -KNIFE was founded by leading T cell and immunology experts who used technology developed at Max Delbrück Center for Molecular Medicine together with Charité – UniversitätiM Berlin, is led by an experienced management group and supported by a leading group of international investors, including Anders Partners, EQT Life Sciences, Ra Capital Management and Versant Ventures. For further information, visit the company’s website at www.t-knife.com.

T-Knife Therapeutics, Inc.
Camille Landis
Chief Business Officer / Chief Financial Officer
[email protected]